Zobrazeno 1 - 10
of 200
pro vyhledávání: ''
Autor:
Yan Yuan, Zhifan Zeng, Rong-Zhen Li, Weiwei Xiao, Hui Chang, Qiaoxuan Wang, Yuanhong Gao, Wei-Hao Xie
Publikováno v:
Cancer Medicine, Vol 11, Iss 1, Pp 117-127 (2022)
Cancer Medicine
Cancer Medicine
Background Anal squamous cell carcinoma (ASCC) is a rare malignant tumor with increasing incidence. The goal of our study was to analyze the treatment outcome and prognostic factors of ASCC in South China in the past half‐century. Methods This stud
Autor:
Mingxuan Zhu, Zhuokai Zhuang, Yumo Xie, Ziying Huang, Yaoyi Huang, Dingcheng Shen, Juan Li, Huichuan Yu, Yanxin Luo, Xiaolin Wang, Rongzhao He, Meijin Huang
Publikováno v:
Cancer Medicine, Vol 10, Iss 24, Pp 8924-8933 (2021)
Cancer Medicine
Cancer Medicine
Objective We conducted this multicenter cohort study to evaluate the current tumor‐node‐metastasis staging system and treatment modality by analyzing the survival outcomes of patient groups with stage III and IV colon cancer. Patients and Methods
Publikováno v:
Cancer Medicine, Vol 10, Iss 23, Pp 8483-8496 (2021)
Cancer Medicine
Cancer Medicine
Background The optimal treatment for elderly patients with esophageal cancer (EC) remains controversial. In the present study, we aimed to investigate whether elderly patients with stage II–III EC could benefit from trimodal therapy. Methods The se
Autor:
Li Pang, Zhiqiang Guo
Publikováno v:
Cancer Medicine, Vol 10, Iss 23, Pp 8558-8569 (2021)
Cancer Medicine
Cancer Medicine
Background There is currently no recognized first‐line treatment strategy for ovarian neuroendocrine tumors (NETs). Furthermore, because of the low incidence of ovarian NETs, no studies have reported prognostic statistics derived from large samples
Autor:
Blanca Polo, Maria Joao Costa, Ana Vagos Mata, C. Lopes, João F. Lacerda, Daniela Alves, Eduardo Espada, João Raposo
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 10, Iss 24, Pp 8768-8776 (2021)
Cancer Medicine, Vol 10, Iss 24, Pp 8768-8776 (2021)
High‐dose methylprednisolone plus rituximab (R‐HDMP) is a useful treatment in chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL) patients unfit for chemo‐immunotherapy and has proven its utility on the treatment of CLL/SLL compl
Publikováno v:
Cancer Medicine, Vol 11, Iss 1, Pp 74-85 (2022)
Cancer Medicine
Cancer Medicine
Objective This study was designed to establish and validate promising and reliable nomograms for predicting the survival of angiosarcoma (AS) patients. Methods The Surveillance, Epidemiology, and End Results database was queried to collect the clinic
Autor:
Tam N M Ngo, Jan Mazur, Eugene S. Chung, Huy Gia Vuong, Vien T. Truong, Vy T. Pham, Binh Q Truong, Quoc Bui, Cassady Palmer
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 10, Iss 24, Pp 8838-8845 (2021)
Cancer Medicine, Vol 10, Iss 24, Pp 8838-8845 (2021)
Background The survival outcome for primary cardiac malignant tumors (PMCTs) based on race has yet to be fully elucidated in previously published literature. This study aimed to address the general long‐term outcome and survival rate differences in
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 10, Iss 24, Pp 8934-8943 (2021)
Cancer Medicine, Vol 10, Iss 24, Pp 8934-8943 (2021)
Background Many real‐world studies of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) are restricted to single centers, limiting the generalizability of their insights. This study aimed to identify important population‐based pre
Autor:
Tetsuya Fukumoto, Naoya Sugihara, Kenichi Nishimura, Noriyoshi Miura, Yuki Miyauchi, Ryuta Watanabe, Yuichiro Sawada, Takashi Saika, Keisuke Funaki, Tadahiko Kikugawa, Kanae Koyama, Toshio Kakuda, Terutaka Noda
Publikováno v:
Cancer Medicine, Vol 10, Iss 22, Pp 7968-7976 (2021)
Cancer Medicine
Cancer Medicine
Background Patients with very‐high‐risk prostate cancer (VHRPCa) have earlier biochemical recurrences (BCRs) and higher mortality rates. It remains unknown whether extended robot‐assisted laparoscopic prostatectomy (eRALP) without neoadjuvant o
Autor:
Teck M Tham, Rohan Malek, Noor Ashani Md Yusoff, Guan C Teh, Rohana Zainal, Say B Lee, Noor Azam Nasuha, Ing S Ngu, Sathiyananthan, Hideyuki Akaza, Jasmine Lim, Murali Sundram, Wei J Koh, Charng C Toh, M-CaP Study, Shankaran Thevarajah, Boon W Teoh, Shamsuddin Omar, Say C Khoo, Teng A Ong, Susan Y Y Woo, Benjamin J T Chui
Publikováno v:
Cancer Medicine, Vol 10, Iss 22, Pp 8020-8028 (2021)
Cancer Medicine
Cancer Medicine
Prostate cancer is the third most common cancer in Malaysia with the lifetime risk of 1 in 117 men. Here, we initiated a longitudinal Malaysia Prostate Cancer (M‐CaP) Study to investigate the clinical and tumour characteristics, treatment patterns